Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.

Toshner MR, Gopalan D, Suntharalingam J, Treacy C, Soon E, Sheares KK, Morrell NW, Screaton N, Pepke-Zaba J.

J Heart Lung Transplant. 2010 Jun;29(6):610-5. doi: 10.1016/j.healun.2009.12.014. Epub 2010 Mar 15.

2.

Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH).

Suntharalingam J, Hughes RJ, Goldsmith K, Doughty N, George P, Toshner M, Sheares KK, Pepke-Zaba J.

Vascul Pharmacol. 2007 Jun;46(6):449-55. Epub 2007 Feb 12.

PMID:
17368113
3.

Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension.

Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR, Sheares KK, Hughes R, Morrell NW, Pepke-Zaba J.

Chest. 2008 Aug;134(2):229-236. doi: 10.1378/chest.07-2681. Epub 2008 Feb 8.

PMID:
18263674
4.

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group.

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan 6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435.

PMID:
18936500
5.

Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension.

Reichenberger F, Voswinckel R, Enke B, Rutsch M, El Fechtali E, Schmehl T, Olschewski H, Schermuly R, Weissmann N, Ghofrani HA, Grimminger F, Mayer E, Seeger W.

Eur Respir J. 2007 Nov;30(5):922-7. Epub 2007 Aug 9.

6.

Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension.

Marini C, Formichi B, Bauleo C, Michelassi C, Prediletto R, Catapano G, Genovesi D, Monti S, Mannucci F, Giuntini C.

Intern Emerg Med. 2013 Jun;8(4):307-16. doi: 10.1007/s11739-011-0610-y. Epub 2011 May 8.

PMID:
21553238
7.

Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?

Chapman TH, Wilde M, Sheth A, Madden BP.

Vascul Pharmacol. 2009 Aug-Sep;51(2-3):90-5. doi: 10.1016/j.vph.2009.04.002. Epub 2009 Apr 20.

PMID:
19386283
8.

Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension.

Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW.

Chest. 2006 Feb;129(2):417-25.

PMID:
16478861
10.

Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients.

Gan CT, Holverda S, Marcus JT, Paulus WJ, Marques KM, Bronzwaer JG, Twisk JW, Boonstra A, Postmus PE, Vonk-Noordegraaf A.

Chest. 2007 Jul;132(1):11-7.

PMID:
17625080
11.

Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?

Madden BP, Sheth A, Wilde M, Ong YE.

Vascul Pharmacol. 2007 Aug-Sep;47(2-3):184-8. Epub 2007 Jun 18.

PMID:
17627899
12.

Exercise pathophysiology and sildenafil effects in chronic thromboembolic pulmonary hypertension.

Claessen G, La Gerche A, Wielandts JY, Bogaert J, Van Cleemput J, Wuyts W, Claus P, Delcroix M, Heidbuchel H.

Heart. 2015 Apr;101(8):637-44. doi: 10.1136/heartjnl-2014-306851. Epub 2015 Feb 16.

PMID:
25686630
13.
14.

Risk Factor Profiles Achieved with Medical Therapy in Prevalent Patients with Pulmonary Arterial and Distal Chronic Thromboembolic Pulmonary Hypertension.

Bartenstein P, Saxer S, Appenzeller P, Lichtblau M, Schwarz EI, Ulrich S.

Respiration. 2018;96(2):127-137. doi: 10.1159/000488000. Epub 2018 Apr 11.

PMID:
29642071
15.

Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension.

Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, Roca J, Barberà JA.

Am J Respir Crit Care Med. 2010 Feb 1;181(3):270-8. doi: 10.1164/rccm.200907-0988OC. Epub 2009 Oct 29.

PMID:
19875684
16.

Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.

Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.

Circulation. 2003 Oct 28;108(17):2066-9. Epub 2003 Oct 20.

PMID:
14568893
17.

Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.

Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.

J Heart Lung Transplant. 2007 Apr;26(4):363-9. Epub 2007 Mar 2.

PMID:
17403478
18.

Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension.

Skoro-Sajer N, Bonderman D, Wiesbauer F, Harja E, Jakowitsch J, Klepetko W, Kneussl MP, Lang IM.

J Thromb Haemost. 2007 Mar;5(3):483-9.

19.

The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease.

Zeng WJ, Lu XL, Xiong CM, Shan GL, Liu ZH, Ni XH, Gu Q, Zhao ZH, Li JJ, He JG; Sildenafil Therapy on Pulmonary Arterial Hypertension Associated With Different Types of Congenital Heart Disease Study Group.

Clin Cardiol. 2011 Aug;34(8):513-8. doi: 10.1002/clc.20917. Epub 2011 Jun 15.

20.

Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.

D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabrò R.

Int J Cardiol. 2012 Mar 22;155(3):378-82. doi: 10.1016/j.ijcard.2010.10.051. Epub 2010 Nov 16.

PMID:
21081251

Supplemental Content

Support Center